Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note issued to investors on Tuesday morning,RTT News reports. The firm currently has a $90.00 price objective on the stock. Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage […]
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note issued to investors on Tuesday morning,RTT News reports. The firm currently has a $90.00 price objective on the stock. Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage […]
